Search Results

Cidara Therapeutics, Inc. today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20.

Cidara Therapeutics, Inc. announced the company will be presenting a poster at the American Society for Microbiology Microbe 2024 conference to be held June 13-17, 2024 at the Georgia World Congress Center in Atlanta, Georgia.

Cidara Therapeutics, Inc. announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq’s requirements for continued listing.

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin.

Cidara Therapeutics, Inc. announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission, in contravention of Nasdaq Listing Rule 5250, could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.